Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

1180503

USP

Dextromethorphan

United States Pharmacopeia (USP) Reference Standard

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C18H25NO
CAS-Nummer:
125-71-3
Molekulargewicht:
271.40
EG-Nummer:
204-752-2
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

dextromethorphan

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

InChI

1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1

InChIKey

MKXZASYAUGDDCJ-NJAFHUGGSA-N

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Dextromethorphan USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

PHR1018

Dextromethorphan HBr, certified reference material, pharmaceutical secondary standard

1181007

Dextromethorphan, United States Pharmacopeia (USP) Reference Standard

D0740000

Dextromethorphan -hydrobromid, European Pharmacopoeia (EP) Reference Standard

Y0000261

Dextromethorphan impurity A, European Pharmacopoeia (EP) Reference Standard

1181040

Dextromethorphan Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR2206

Dextromethorphan N-Oxide HCl, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1976

Dextromethorphan Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

Piktogramme

Skull and crossbonesEnvironment
GHS06,GHS09

Signalwort

Danger

H-Sätze

H301,H411

Gefahreneinstufungen

Acute Tox. 3 Oral - Aquatic Chronic 2

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

4-(Butylamino)benzoesäure 97%

Sigma-Aldrich

262412

4-(Butylamino)benzoesäure

Dextrorphan tartrate powder

Sigma-Aldrich

D127

Dextrorphan tartrate

Docusatnatrium United States Pharmacopeia (USP) Reference Standard

USP

1224802

Docusatnatrium

Dextrorphan tartrate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1974

Dextrorphan tartrate

Flumazenil >99% (HPLC), solid

Sigma-Aldrich

F6300

Flumazenil

Tolbutamid analytical standard

Supelco

T0891

Tolbutamid

Phenacetin ≥98.0% (HPLC)

Sigma-Aldrich

77440

Phenacetin

Eric Guenin et al.
Clinical drug investigation, 34(9), 609-616 (2014-07-17)
Dextromethorphan hydrobromide (DM) is a widely used antitussive. This study determined, for the first time, the basic pharmacokinetic profile of DM and its active metabolite, dextrorphan (DP) in children and adolescents. Thirty-eight male and female subjects at risk for developing
Rüdiger Kaspera et al.
Biochemical pharmacology, 91(1), 109-118 (2014-06-29)
Ritonavir, an HIV protease inhibitor, is successfully used for the prevention and treatment of HIV infections. Ritonavir pharmacokinetics are complicated by inhibition, induction and pharmacogenetics of cytochrome P450 (CYP) enzymes mediating its clearance. This investigation revealed that CYP2J2, along with
Sang Yoon Lee et al.
Xenobiotica; the fate of foreign compounds in biological systems, 45(2), 131-138 (2014-08-26)
1. The herb-drug interaction potential of Hwang-Ryun-Hae-Dok-Tang (HR) extracts mediated by cytochrome P450 (CYP) inhibition was determined using human liver microsomes. 2. HR strongly inhibited CYP1A2 and moderately inhibited CYP2C19, CYP2D6, and CYP3A4 (testosterone) but not CYP2A6, CYP2B6, CYP2C8, CYP2C9, and CYP3A4
Jasbir D Upadhyaya et al.
PloS one, 9(10), e110373-e110373 (2014-10-24)
Activation of bitter taste receptors (T2Rs) in human airway smooth muscle cells leads to muscle relaxation and bronchodilation. This finding led to our hypothesis that T2Rs are expressed in human pulmonary artery smooth muscle cells and might be involved in
Sang Yoon Lee et al.
Toxicology letters, 229(1), 33-40 (2014-06-10)
Although cytochrome P450 inhibition is the major drug-drug interaction (DDI) mechanism in clinical pharmacotherapy, DDI of a number of well-established drugs have not been investigated. Rifampicin, isoniazid, pyrazinamide and ethambutol combination therapy inhibits clearance of theophylline in patients with tuberculosis.
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.